How to Choose a Compounding Pharmacy for Egrifta (Tesamorelin)

What Tesamorelin Is and Why Compounding Exists

Tesamorelin is a stabilized synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). The brand product Egrifta SV, manufactured by Theratechnologies, carries a single FDA-approved indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. [1]

Outside that narrow label, many patients and prescribers are interested in tesamorelin for its well-documented effect on visceral adipose tissue, body composition, and IGF-1 levels in non-HIV populations. Because Egrifta SV is expensive (retail pricing commonly exceeds $4,000 per month without insurance) and insurance coverage is tightly restricted, compounding pharmacies have filled a real market gap. [2]

The Legal Basis for Compounding Tesamorelin

Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) govern pharmacy compounding. A 503A pharmacy prepares patient-specific prescriptions; a 503B outsourcing facility produces larger batches for office use without individual prescriptions. Both must comply with applicable USP standards. [3]

Compounded tesamorelin is not an FDA-approved drug. It is only legal when a licensed prescriber writes an individualized prescription based on a documented clinical need that the FDA-approved product cannot meet, whether because of a different dosage form, documented allergy to an excipient, or a cost-access barrier recognized in state law.

The FDA periodically evaluates whether a compounded peptide appears on its list of "essentially a copy" drugs. As of early 2025, tesamorelin has not been placed on the FDA 503A Bulks List as a prohibited substance, but the regulatory environment continues to shift. Prescribers should verify current status at FDA.gov before initiating therapy. [4]

Why the Compounding Market Carries Real Risk

Between 2018 and 2024, the FDA issued more than 60 warning letters to compounding pharmacies, a significant portion related to sterility failures and misrepresentation of peptide purity. [5] A 2012 fungal meningitis outbreak traced to contaminated methylprednisolone acetate from New England Compounding Center killed 64 people and injured hundreds, prompting the Drug Quality and Security Act (DQSA) of 2013. That legislation created the modern 503B framework precisely because uncontrolled compounding carries serious patient-safety consequences. [6]

Tesamorelin is a sterile injectable peptide. The failure modes, microbial contamination, incorrect peptide sequence, sub-potent or super-potent dosing, endotoxin burden, are identical in mechanism to those that caused the meningitis outbreak. That context shapes every recommendation in this article.

The Regulatory Framework Every Buyer Must Understand

Navigating compounding regulations can feel like reading a multilayered legal document. The short version: federal law sets the floor, state boards of pharmacy set the ceiling, and USP standards are the technical specifications that define "acceptable" for any sterile product.

USP <797>: The Sterility Standard for Injectable Peptides

USP <797> is the compendial standard for sterile compounding. The 2023 revision (effective November 2023) tightened environmental monitoring, personnel training requirements, and beyond-use dating. [7] Any pharmacy compounding injectable tesamorelin must operate a classified cleanroom, typically an ISO 5 primary engineering control inside an ISO 7 or ISO 8 buffer room, and must conduct routine viable air and surface sampling.

Key USP <797> checkpoints to ask about:

• Sterility testing schedule (at minimum for Category 3 preparations, sterility testing is required)
• Environmental monitoring logs available for inspection
• Personnel garbing and media-fill competency records
• Beyond-use date (BUD) support documentation

USP <795> and Non-Sterile Tesamorelin Products

Some providers market oral or sublingual tesamorelin preparations. Because tesamorelin is a 44-amino-acid peptide with essentially zero oral bioavailability, these preparations have no established clinical efficacy pathway. USP <795> governs non-sterile compounding, but no non-sterile dosage form of tesamorelin has demonstrated pharmacokinetic parity with the injectable form. [8] Patients asking about oral or sublingual tesamorelin should treat that offering as a red flag regarding the pharmacy's scientific credibility.

State Board Licensure and Interstate Shipping

A 503A pharmacy must hold an active license in every state to which it ships compounded prescriptions. Verification takes 90 seconds: the National Association of Boards of Pharmacy (NABP) "Not Recommended" list, available at nabp.pharmacy, names operations that regulators have flagged. Cross-reference the pharmacy's state license number with that state's board of pharmacy lookup before ordering.

Quality Testing Standards: What the CoA Must Show

A certificate of analysis (CoA) is a written report from an independent, accredited laboratory confirming the identity, purity, potency, and safety profile of the compounded product. Requesting a CoA is the single most effective quality screen available to a prescriber or patient.

HPLC Purity Testing

High-performance liquid chromatography (HPLC) separates the target peptide from related impurities, degradation products, and synthesis byproducts. For a clinically acceptable tesamorelin preparation, HPLC purity should read at least 98% by area, with individual unknown impurities below 0.5%. Some high-quality compounders achieve 99%+ purity on routine testing. [9]

Ask specifically whether the CoA uses reverse-phase HPLC (RP-HPLC) with UV detection at 220 nm. This is the industry-standard method for peptide purity quantitation. Mass spectrometry confirmation of molecular weight (MW approximately 5,135 Da for tesamorelin) should accompany any CoA from a rigorous lab. [10]

Endotoxin and Sterility Testing

Bacterial endotoxins cause fever, septic shock, and, at high doses, death. The FDA's general limit for parenteral drugs is <5 EU/kg/hr based on the intended dose. [11] For typical tesamorelin doses (1 mg to 2 mg subcutaneous daily), the allowable endotoxin burden per vial is small, and a well-run pharmacy should consistently test well below this threshold.

Sterility testing per USP <71> requires incubation in aerobic and anaerobic media for 14 days. Ask the pharmacy for the batch sterility result, not just a statement of compliance.

Peptide Sequence Confirmation

Incorrect amino acid sequences can produce immunogenic or pharmacologically inactive peptides. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) or Edman degradation sequencing can confirm the correct 44-residue sequence. Not every compounder offers this routinely, but top-tier facilities do.

The table below summarizes the minimum CoA requirements that HealthRX's medical team uses when evaluating a new compounding partner for tesamorelin prescriptions.

| Test | Method | Minimum Acceptable Result | |---|---|---| | Peptide purity | RP-HPLC, UV 220 nm | ≥98% area | | Molecular weight | ESI-MS or MALDI-TOF | 5,135 ± 2 Da | | Endotoxin | LAL kinetic turbidimetric | <5 EU/kg/hr at prescribed dose | | Sterility | USP <71>, 14-day dual media | No growth | | pH | Potentiometry | 4.5 to 6.5 | | Appearance | Visual/particulate | Clear, colorless, particle-free |

PCAB Accreditation and Why It Matters

The Pharmacy Compounding Accreditation Board (PCAB) is the only national accreditation program purpose-built for compounding pharmacies. PCAB accreditation requires on-site inspection, review of standard operating procedures, staff competency verification, and ongoing quality audits. [12]

PCAB-accredited pharmacies are not automatically safe, but accreditation substantially raises the probability of consistent quality. The accreditation directory is publicly searchable at pcab.org. A pharmacy that claims PCAB accreditation but does not appear in the directory is lying, which tells you everything you need to know about how they would handle quality documentation.

ISO-Certified Reference Laboratories

Even a non-PCAB pharmacy can demonstrate quality through independent ISO 17025-accredited laboratory testing. ISO 17025 is the international standard for testing and calibration laboratory competence. [13] When a CoA is generated by an ISO 17025 lab, the methodology and result interpretation meet internationally audited standards.

Ask the pharmacy: "Which third-party laboratory performs your peptide purity and endotoxin testing, and is that lab ISO 17025 accredited?" A prompt, specific answer with a lab name you can verify is a good sign. Vague answers are not.

Where Egrifta (Tesamorelin) Can Be Legally Obtained

FDA-Approved Brand Product

The simplest legal pathway is the branded product, Egrifta SV (tesamorelin 2 mg/vial), distributed by Theratechnologies USA. Patients with HIV lipodystrophy who meet label criteria may access it through specialty pharmacy channels with prior authorization. [1]

503A Compounding Pharmacies

For off-label prescriptions, a licensed 503A pharmacy can compound tesamorelin based on an individualized prescriber order. The compounder must use an FDA-registered bulk drug substance supplier and comply with USP <797>. As of 2025, tesamorelin bulk substance is available from several FDA-registered API suppliers, which means 503A compounding is legally viable when all other conditions are met. [4]

503B Outsourcing Facilities

A 503B outsourcing facility can produce tesamorelin in larger batch quantities for physician-office dispensing without patient-specific prescriptions, provided tesamorelin appears on the FDA's 503B Bulks List. Verify current list status at FDA.gov before relying on this pathway. [4]

What Is Never Legal: "Research Use Only" Suppliers

Websites selling tesamorelin labeled "research use only," "not for human consumption," or "for in-vitro use only" occupy a legal gray zone that is firmly on the wrong side of the law when a human injects the product. The FDA has taken enforcement action against multiple such vendors. [5] These suppliers have no obligation to test for purity, sterility, or correct sequence. Clinical case reports and online forums document serious adverse events from contaminated peptides sourced this way, including injection-site abscesses, systemic infections, and iatrogenic acromegaly from mislabeled products. [14]

Practical Buyer Guidance: A Step-by-Step Verification Process

The following sequence applies whether a prescriber is selecting a pharmacy to work with or a patient is evaluating one presented to them.

Step 1. Confirm State Licensure

Look up the pharmacy's license on the relevant state board of pharmacy website. The license should be active, not expired or suspended. Then check the NABP "Not Recommended" list. This takes under five minutes and filters out the most obvious bad actors.

Step 2. Ask for the Facility's USP <797> Compliance Documentation

A legitimate sterile compounder will have recent environmental monitoring reports, cleanroom certification records, and a current facility audit. They should not hesitate to share summaries of these. Refusal to provide any documentation is disqualifying.

Step 3. Request a Product-Specific CoA

Ask for the CoA for the specific lot number you are about to receive, not a generic template. The CoA should include the testing lab's name, accreditation status, methodology, numeric results (not just "pass"), and the analyst's signature. Compare the purity and endotoxin values against the minimum benchmarks in the table above.

Step 4. Verify the Bulk Drug Substance Source

Ask whether the tesamorelin bulk API (active pharmaceutical ingredient) is sourced from an FDA-registered supplier. The FDA maintains a database of registered drug establishments at accessdata.fda.gov. [15] Unregistered API sources are a supply-chain integrity failure that no downstream testing can fully rescue.

Step 5. Check for PCAB Accreditation or Equivalent

Confirm accreditation in the PCAB directory. If not PCAB, ask which accreditation body has inspected the facility, when, and what the outcome was. Request the inspection summary.

Step 6. Evaluate Prescription Handling

A legitimate compounding pharmacy requires a valid prescription from a licensed prescriber before dispensing. Any pharmacy that ships tesamorelin without a prescription is operating outside federal law, regardless of how the product is labeled.

Red Flags: When to Walk Away Immediately

Even experienced prescribers occasionally miss warning signs. The following behaviors should trigger an immediate stop.

No CoA available on request. Any pharmacy that cannot produce an analytical CoA for the specific lot you are receiving has no evidence that the product is what it claims to be.

Pricing far below market. High-quality sterile compounding is expensive. Cleanroom maintenance, environmental monitoring, third-party testing, and qualified personnel cost money. A price of $30 for a 10 mg vial of tesamorelin signals that corners are being cut somewhere in the quality chain.

"Research use only" labeling combined with a checkout cart. This is a regulatory workaround, not a legitimate designation.

No prescription required. Full stop.

Unverifiable PCAB claim. Cross-check in the public directory. Fraudulent accreditation claims appear more often than most patients expect.

No pharmacist contact information. Federal law requires a pharmacist to be available for patient consultation. A pharmacy that provides only a web form with no phone number or licensed pharmacist name is not operating lawfully.

The Clinical Evidence Base: Why Tesamorelin Is Worth Getting Right

Getting the sourcing right matters because tesamorelin has genuine, well-documented clinical efficacy when the correct peptide is delivered at the correct dose.

Key Efficacy Data

In the two key Phase 3 trials (STEPS, combined N=816), tesamorelin 2 mg subcutaneous daily reduced visceral adipose tissue by a mean of 18% vs. A 5% reduction in the placebo group (P<0.001) at 26 weeks. [16] The Endocrine Society's 2021 clinical practice guideline on adult growth hormone deficiency notes that GHRH analogues produce IGF-1 normalization in a significant proportion of GHD patients, though the guideline stops short of endorsing off-label compounded tesamorelin for non-HIV indications. [17]

The guideline states directly: "We suggest that treatment be individualized and that providers discuss both the benefits and risks of GH-axis stimulation, including potential effects on glucose metabolism." [17] This underscores why physician oversight, pharmacy quality, and correct dosing are inseparable.

IGF-1 Monitoring as a Quality Surrogate

One indirect way to assess whether a compounded tesamorelin preparation is at labeled potency is to monitor IGF-1 response. A patient injecting correctly stored, correctly dosed tesamorelin at 1 to 2 mg daily should see IGF-1 rise toward the upper quartile of the age-adjusted reference range within 4 to 8 weeks. [18] No IGF-1 response after 6 to 8 weeks of documented daily injections suggests either product degradation (temperature excursion, reconstitution error) or sub-potent API. This is not a substitute for pharmacy-level quality testing, but it provides a clinical checkpoint.

Adverse Effect Profile and Why Purity Matters

The known adverse effects of pharmaceutical-grade tesamorelin include fluid retention, arthralgias, myalgias, insulin resistance, and injection-site reactions. [1] Impure or contaminated compounded preparations add an entirely separate risk layer: host immune responses to peptide impurities, endotoxin reactions (fever, rigors, hypotension), and, in worst-case scenarios, systemic infection from non-sterile product. A 2021 FDA safety communication highlighted injection-site infections requiring surgical drainage in patients using non-sterile compounded peptides. [5] Purity is not a quality-of-life nicety. It is the difference between a drug and a hazard.

A Note on Telehealth Prescribing and Tesamorelin

Many patients first encounter tesamorelin through telehealth platforms. A telehealth prescriber operating lawfully will conduct a documented medical evaluation, order baseline labs (IGF-1, fasting glucose, HbA1c), review contraindications including active malignancy and pituitary disease, and direct the prescription to a verified, licensed compounding pharmacy. [17]

Platforms that skip lab requirements, prescribe without a synchronous clinical evaluation, or permit patients to select their own unverified pharmacy are cutting corners that the medical and regulatory communities have agreed are non-negotiable. The American Association of Clinical Endocrinology (AACE) position on GH-axis therapy requires documented deficiency or an approved indication before treatment. [19]

Storing and Reconstituting Compounded Tesamorelin Correctly

Even a perfect vial becomes a hazard with improper handling. Compounded tesamorelin is typically lyophilized (freeze-dried). Key storage and reconstitution points:

• Store lyophilized vials at 2 to 8 degrees Celsius (refrigerator temperature). Do not freeze.
• Use only the supplied bacteriostatic water for injection (BWFI) or sterile water for injection as directed on the pharmacy label.
• After reconstitution, use within the compounder's stated BUD, typically 28 days refrigerated for benzyl-alcohol-preserved formulations under USP <797> 2023 Category 2 rules.
• Never use a vial that appears cloudy or contains visible particles after reconstitution.
• Rotate injection sites (abdomen, thigh) to reduce subcutaneous tissue changes at the injection site.

The FDA's MedWatch program accepts voluntary adverse event reports for compounded products. Prescribers and patients who observe unexpected reactions should file a report at fda.gov/safety/medwatch. [20]